AP-SA02
AXP000221.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- Armata Pharmaceuticals
- Sponsor
- Armata Pharmaceuticals
Names
| Name | Type | Source |
|---|---|---|
| AP-SA02 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Staphylococcus aureus bacteriophage (cocktail)
- Replication
- replicating
- Route
- intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05184764 | Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia | Completed | Phase 1/2 | 2022-04-26 | 2024-11-07 | 56 | Bacteremia; Bacteremia Due to Staphylococcus Aureus; Bacteremia Staph; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 43010175 | Engineered bacteriophages as precision antimicrobials against multidrug-resistant ESKAPE pathogens: molecular engineering strategies, clinical translation, and the crystallizing global regulatory landscape. | Future science OA | 2026 | name in abstract: AP-SA02 |
Notes
Intravenous multi-phage product against Staphylococcus aureus bacteraemia. Phase 1b/2a diSArm NCT05184764, topline reported 2025. A later product than AB-SA01 and entered separately.
How to cite
AP-SA02 (AXP000221.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000221.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.